{"meta":{"totalResults":6,"from":0},"results":[{"aliases":[{"type":"CASRegistryName","name":"154229-19-3"},{"type":"ChemicalStructureName","name":"17-(3-pyridyl)androsta-5,16-dien-3beta-ol"},{"type":"CodeName","name":"CB 7598"}],"definition":{"html":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","text":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels."},"drugInfoSummaryLink":null,"nciConceptId":"C77333","nciConceptName":"Abiraterone","termId":810653,"name":"abiraterone","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone"},{"aliases":[{"type":"CodeName","name":"CB7630"},{"type":"CodeName","name":"CB 7630"},{"type":"CodeName","name":"CB-7630"},{"type":"USBrandName","name":"Zytiga"},{"type":"USBrandName","name":"Yonsa"},{"type":"CodeName","name":"BR9004"},{"type":"CodeName","name":"BR9004-1"},{"type":"CASRegistryName","name":"154229-18-2"},{"type":"ChemicalStructureName","name":"17-(3-pyridyl)-5,16-androstadien-3beta-acetate"},{"type":"ChemicalStructureName","name":"androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-"},{"type":"CodeName","name":"JNJ-212082"}],"definition":{"html":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","text":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/abirateroneacetate","text":"Abiraterone Acetate"},"nciConceptId":"C68845","nciConceptName":"Abiraterone Acetate","termId":552704,"name":"abiraterone acetate","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-acetate"},{"aliases":[{"type":"CodeName","name":"DST-2970"},{"type":"Synonym","name":"abiraterone KinetiSol formulation DST-2970"},{"type":"CodeName","name":"DST 2970"},{"type":"CodeName","name":"DST2970"}],"definition":{"html":"An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","text":"An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels."},"drugInfoSummaryLink":null,"nciConceptId":"C175940","nciConceptName":"Abiraterone Amorphous Solid Dispersion Formulation DST-2970","termId":803232,"name":"abiraterone amorphous solid dispersion formulation DST-2970","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-amorphous-solid-dispersion-formulation-dst-2970"},{"aliases":[{"type":"Synonym","name":"PRL-02 depot"},{"type":"CodeName","name":"PRL-02"},{"type":"CodeName","name":"PRL 02"},{"type":"CodeName","name":"PRL02"}],"definition":{"html":"A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.","text":"A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C179617","nciConceptName":"Abiraterone Decanoate Depot","termId":804911,"name":"abiraterone decanoate depot","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-decanoate-depot"},{"aliases":[{"type":"Synonym","name":"abiraterone-prednisone"},{"type":"Synonym","name":"abiraterone/prednisone"},{"type":"Synonym","name":"prednisone-abiraterone"},{"type":"Synonym","name":"prednisone-abiraterone regimen"},{"type":"Synonym","name":"prednisone/abiraterone"}],"definition":{"html":"A regimen consisting of abiraterone and prednisone that can be used for the treatment of prostate cancer and salivary gland tumors.","text":"A regimen consisting of abiraterone and prednisone that can be used for the treatment of prostate cancer and salivary gland tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C160503","nciConceptName":"Abiraterone/Prednisone Regimen","termId":818155,"name":"abiraterone/prednisone regimen","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-prednisone-regimen"},{"aliases":[{"type":"Synonym","name":"abiraterone acetate/niraparib tosylate monohydrate"},{"type":"CodeName","name":"CJNJ-67652000"},{"type":"Synonym","name":"niraparib/abiraterone acetate"},{"type":"Synonym","name":"abiraterone acetate and niraparib tosylate monohydrate"},{"type":"USBrandName","name":"Akeega"},{"type":"Synonym","name":"niraparib and abiraterone acetate"},{"type":"Synonym","name":"abiraterone acetate/niraparib"},{"type":"Synonym","name":"niraparib tosylate monohydrate/abiraterone acetate"}],"definition":{"html":"An orally bioavailable fixed dose combination agent containing the acetate ester prodrug of the steroidal compound abiraterone, an inhibitor of the cytochrome p450 (CYP) family member 17 alpha-hydroxylase/C17,20-lyase (CYP17; CYP17A1), and the tosylate monohydrate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with anti-androgen and antineoplastic activities. Upon administration of niraparib tosylate monohydrate and abiraterone acetate, abiraterone acetate is converted to its active form abiraterone, which, in turn, targets, binds to and inhibits the enzymatic activity of CYP17, thereby preventing the formation of steroid intermediates and androgens involved in androgen synthesis. This suppresses testosterone production by testes, adrenals and testosterone-dependent prostate tumor cells in order to decrease testosterone to castrate-range levels, which inhibits proliferation of testosterone-dependent cancer cells. In addition, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, and promoting genomic instability, which results in cancer cell apoptosis. PARP family proteins are often overexpressed in cancer cells and are activated by single-strand DNA (ssDNA) breaks to catalyze post-translational ADP-ribosylation of nuclear proteins, which promotes DNA repair and cancer cell survival.","text":"An orally bioavailable fixed dose combination agent containing the acetate ester prodrug of the steroidal compound abiraterone, an inhibitor of the cytochrome p450 (CYP) family member 17 alpha-hydroxylase/C17,20-lyase (CYP17; CYP17A1), and the tosylate monohydrate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with anti-androgen and antineoplastic activities. Upon administration of niraparib tosylate monohydrate and abiraterone acetate, abiraterone acetate is converted to its active form abiraterone, which, in turn, targets, binds to and inhibits the enzymatic activity of CYP17, thereby preventing the formation of steroid intermediates and androgens involved in androgen synthesis. This suppresses testosterone production by testes, adrenals and testosterone-dependent prostate tumor cells in order to decrease testosterone to castrate-range levels, which inhibits proliferation of testosterone-dependent cancer cells. In addition, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, and promoting genomic instability, which results in cancer cell apoptosis. PARP family proteins are often overexpressed in cancer cells and are activated by single-strand DNA (ssDNA) breaks to catalyze post-translational ADP-ribosylation of nuclear proteins, which promotes DNA repair and cancer cell survival."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/niraparib-tosylate-monohydrate-and-abiraterone-acetate","text":"Niraparib Tosylate Monohydrate and Abiraterone Acetate"},"nciConceptId":"C191876","nciConceptName":"Abiraterone Acetate/Niraparib","termId":811466,"name":"niraparib tosylate monohydrate and abiraterone acetate","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-acetate-niraparib"}],"links":null}